Chowdhury Simon, Pickering Lisa, Ellis Paul
Department of Medical Oncology, Guy's Hospital, London, UK.
J Br Menopause Soc. 2006 Dec;12(4):172-4. doi: 10.1258/136218006779160517.
Over-expression of the human epidermal growth factor receptor 2 (HER2) protein, amplification of the HER2 gene or both occur in 15-25% of breast cancers and are associated with aggressive tumour behaviour. Trastuzumab (Herceptin), a humanized murine monoclonal antibody against the HER2 protein, has been shown to benefit patients with HER2-positive metastatic breast cancer when administered alone or in combination with chemotherapy. When to start therapy, the duration of treatment, adjuvant chemotherapy regimens and cardiotoxicity issues are examined.
人类表皮生长因子受体2（HER2）蛋白过表达、HER2基因扩增或两者同时出现于15%至25%的乳腺癌中，并与侵袭性肿瘤行为相关。曲妥珠单抗（赫赛汀）是一种针对HER2蛋白的人源化鼠单克隆抗体，已证明单独使用或与化疗联合使用时，对HER2阳性转移性乳腺癌患者有益。本文探讨了何时开始治疗、治疗持续时间、辅助化疗方案及心脏毒性问题。
